Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000892279 | SCV001036142 | benign | not provided | 2024-01-25 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000892279 | SCV001841101 | benign | not provided | 2020-01-29 | criteria provided, single submitter | clinical testing | This variant is associated with the following publications: (PMID: 32172663, 30377194, 27389715, 23670291, 31135094, 19643476, 29296762) |
Genetic Services Laboratory, |
RCV000121244 | SCV002066044 | benign | not specified | 2021-05-18 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002492429 | SCV002804160 | benign | Primary familial polycythemia due to EPO receptor mutation; Acquired polycythemia vera; Budd-Chiari syndrome; Primary myelofibrosis; Acute myeloid leukemia; Thrombocythemia 3 | 2022-04-22 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000892279 | SCV004161836 | benign | not provided | 2024-03-01 | criteria provided, single submitter | clinical testing | JAK2: BS1, BS2 |
ARUP Laboratories, |
RCV000892279 | SCV004564044 | likely benign | not provided | 2023-03-06 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003915208 | SCV004732306 | likely benign | JAK2-related disorder | 2021-10-06 | criteria provided, single submitter | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |
ITMI | RCV000121244 | SCV000085415 | not provided | not specified | 2013-09-19 | no assertion provided | reference population |